IWR-1-endo

Catalog No.S7086 Synonyms: endo-IWR 1, IWR-1

For research use only.

IWR-1-endo (endo-IWR 1, IWR-1) is a Wnt pathway inhibitor with IC50 of 180 nM in L-cells expressing Wnt3A, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.

IWR-1-endo Chemical Structure

CAS No. 1127442-82-3

Selleck's IWR-1-endo has been cited by 81 publications

Purity & Quality Control

Choose Selective Wnt/beta-catenin Inhibitors

Other Wnt/beta-catenin Products

Biological Activity

Description IWR-1-endo (endo-IWR 1, IWR-1) is a Wnt pathway inhibitor with IC50 of 180 nM in L-cells expressing Wnt3A, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.
Targets
Wnt [1]
(L-cells expressing Wnt3A)
180 nM
In vitro

Although both IWR-1 and XAV939 act as reversible Wnt pathway inhibitors and exhibit similar pharmacological effects both in vitro and in vivo, IWR-1 exerts its effect via interaction with Axin, while XAV939 binds TNKS directly. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BL21 (DE3) NHnNTIdHfW6ldHnvckBie3OjeR?= M{frNFkxKG2rboO= MoLGRYN1cX[rdImgc4YhVi22ZYLtbY52eyCqZYjhTIl{NXSjZ3fl[EBpfW2jbjDUUnNMOiCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy|IIXzbY5oKGKrb4Tpcplt[XSnZDDORWQsKGG|IIP1ZpN1emG2ZTDh[pRmeiB7MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whTUN3MDC9JFAvOiEQvF2u M365TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkOzN|IxLz5{MkKzN|MzODxxYU6=
SW480 MoX6SpVv[3Srb36gZZN{[Xl? MnewNlQhcHK| MWjJcohq[mm2aX;uJI9nKHSjbnv5doF{\SCrbjDoeY1idiCVV{S4NEBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[gZZhqdjJiYX\0[ZIhOjRiaILzJIJ6KEixZXPod5Qh\HmnLXLhd4VlKG2ndHjv[EwhTUN3MDC9JFIvPSEQvF2u MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyMUWxO{c,OjN5MEG1NVc9N2F-
HEK293T MUnGeY5kfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGKndHGtZ4F{\WmwLXTldIVv\GWwdDDjZY5wdmmlYXygW451OyCyYYToe4F6KGmwIHj1cYFvKEiHS{K5N3Qh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNlYh|ryPLh?= MlXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzOUG1OVcoRjJ{MUmxOVU4RC:jPh?=
SW480 MorCSpVv[3Srb36gZZN{[Xl? M4XNNFQxKHSxIES4JIhzew>? NHPGOpNKdmirYnn0bY9vKG:oIIThcot6emG|ZTDpckBpfW2jbjDTW|Q5OCClZXzsd{Bie3Onc4Pl[EBieyCmZXfyZYRifGmxbjDv[kBj\XSjIHPheIVvcW5iYX\0[ZIhPDBidH:gOFghcHK|LDDJR|UxKD1iMD6yOUDPxE1w NYLuTpFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFE2OTdpPkKzO|AyPTF5PD;hQi=>
L-Wnt-STF NESy[mlHfW6ldHnvckBie3OjeR?= MUKyOEBpenN? MoGwTY5pcWKrdHnvckBw\iCWTlvTMVIhcW5ibX;1d4UhVC2ZboStV3RHKGOnbHzzJIF{e2W|c3XkJIF{KGSrc4L1dJRqd25ib3[gW451KHOrZ37hcIlv\yCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wOVYh|ryPLh?= Mnq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mke3PVIoRjJ2NUK3O|kzRC:jPh?=
L-Wnt-STF MmrxSpVv[3Srb36gZZN{[Xl? NFrXUmgzPCCqcoO= MofoTY5pcWKrdHnvckBw\iCWTlvTMVEhcW5ibX;1d4UhVC2ZboStV3RHKGOnbHzzJIF{e2W|c3XkJIF{KGSrc4L1dJRqd25ib3[gW451KHOrZ37hcIlv\yCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6xN|Eh|ryPLh?= Mn\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mke3PVIoRjJ2NUK3O|kzRC:jPh?=
HT29 MWPGeY5kfGmxbjDhd5NigQ>? MYWyOEBpenN? MVXJcohq[mm2aX;uJI9nKFewdDDzbYdv[WyrbnegbY4hcHWvYX6gTHQzQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIJmfGFvY3H0[Y5qdi2vZXTpZZRm\CCWY3[vUIVnKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBi\nSncjCyOEBpenNiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEwhUUN3MDC9JFI1NjRizszNMi=> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MES4PUc,OjR7NUC0PFk9N2F-
DLD1 NEjMbldHfW6ldHnvckBie3OjeR?= MmHrNVAhfU1? MWPJcoR2[3Srb36gc4YhSXirbkKgbY4hcHWvYX6gSGxFOSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDJW3IuUVNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hX262IIDheIh4[XliYXP0bZZqfHliYYSgNVAhfU1iYomgV3RHKHKncH;yeIVzKGG|c3H5JI1mfGixZB?= MlPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
HEK293 MWDGeY5kfGmxbjDhd5NigQ>? NGrvOZpFcXOybHHj[Y1mdnRib3[gTXdTNVCEIH\yc40hSXirbkKgbY4hUEWNMkmzJINmdGy|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q> MnXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 NFr6VFRHfW6ldHnvckBie3OjeR?= NXHUPXVTUW6qaXLpeIlwdiCxZjDBfIlvOiCycn;0[YlvKGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 MlW5SpVv[3Srb36gZZN{[Xl? MX7JcoR2[3Srb36gc4YhSXirbkKgZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hXGi{NEGgdIhwe3Cqb4L5cIF1\WRiYnX0ZU1k[XOnaX6gcIV3\Wy|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NUXhe4VjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 MUXGeY5kfGmxbjDhd5NigQ>? NIf1b2RKdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iU3XyN|cheGixc4Doc5J6dGG2ZXSgZoV1[S2lYYPlbY4hdGW4ZXzzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MkTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 NIDucJRHfW6ldHnvckBie3OjeR?= NYfZe3R1TGWlcnXhd4UhcW5iYnX0ZU1k[XOnaX6gZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiZYjwdoV{e2mwZzDpckBCWENibYX0ZY51 NGe0bnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 NU\kZlRNTnWwY4Tpc44h[XO|YYm= MW[yJIhzew>? Mn35TY5lfWO2aX;uJI9nKEG6aX6yJJN1[WKrbHn6ZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[YQhfHKjboPjdolxfGmxbjDv[kBCgGmwMjDh[pRmeiB{IHjyd{BjgSCUVD3QR3IhdWW2aH;k NFvqV489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 MWjGeY5kfGmxbjDhd5NigQ>? MoPVTY5lfWO2aX;uJI9nKEG6aX6yJIFk[3WvdXzheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKG[{ZXWgZoV1[S2lYYPlbY4hdGW4ZXzzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MlHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 MonuSpVv[3Srb36gZZN{[Xl? M1mxTWlv\HWldHnvckBw\iCDeHnuNkB{fGGkaXzpfoF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDXcpQw[mW2YT3jZZNmcW5icHH0bJdigQ>? MkDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 NWLFNFFqTnWwY4Tpc44h[XO|YYm= NIOxNY5KdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iU3XyN|MheGixc4Doc5J6dGG2ZXSgZoV1[S2lYYPlbY4hdGW4ZXzzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NUL4R|JCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 MnvpSpVv[3Srb36gZZN{[Xl? M2m2Rmlv\HWldHnvckBw\iCDeHnuNkBi[2O3bYXsZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MnXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 MlTHSpVv[3Srb36gZZN{[Xl? MnPWNUB1dyB{MDD1US=> M2qyfFI1KGi{cx?= MkHpTY5pcWKrdHnvckBw\iC2YX7rfZJie2ViaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTDSk1l\XCnbnTlcpQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIF1KDFidH:gNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KGS3YXygcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 NGDKWXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyO|c6Oid-MkS1Nlc4QTJ:L3G+
DLD1 M3L1ZmN6fG:2b4jpZ4l1gSCjc4PhfS=> MmPsNUB1dyB{MDD1US=> NHnZRXoyOCCmYYnz NHLPUplEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFVERzIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHH0JFEhfG9iMkCgeW0hdWWjc4Xy[YQhd25iZHH5JFExKGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5o Mo\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mke3PVIoRjJ2NUK3O|kzRC:jPh?=
HT29 NWHxZ2VbTnWwY4Tpc44h[XO|YYm= M2X0clI2KHWP NGG1T|IzPCCqcoO= M1ThWWlvcGmkaYTpc44hd2ZiV370JJNq\26jbHnu[{BqdiCqdX3hckBJXDJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[mW2YT3jZZRmdmmwLX3l[IlifGWmIGTj[k9N\WZidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGG2IEK1JJVOKGGodHXyJFI1KGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUBz\WyjdHn2[UB1dyClb370do9t MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MES4PUc,OjR7NUC0PFk9N2F-
HT29 MVnGeY5kfGmxbjDhd5NigQ>? MlfONlUhfU1? NInhOWMzPCCqcoO= MV7Jcohq[mm2aX;uJI9nKFewdDDzbYdv[WyrbnegbY4hcHWvYX6gTHQzQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIJmfGFvY3H0[Y5qdi2vZXTpZZRm\CCWY3[vUIVnKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBifCB{NTD1UUBi\nSncjCyOEBpenNiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEBqdiCycnXz[Y5k\SCxZjDHV2suO2KndHGgbY5pcWKrdH;yJGxqS2x? MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUC0PFkoRjJ2OUWwOFg6RC:jPh?=
HT29 NIW1TFhHfW6ldHnvckBie3OjeR?= NVrFXGlJOjVidV2= M3G3WlI1KGi{cx?= NHeyd29KdmirYnn0bY9vKG:oIGfueE9j\XSjLXPheIVvcW5ic3nncoFtcW6pIHnuJIh2dWGwIFjUNlkh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iYYjpclIhdVKQQTDlfJBz\XO|aX;uJIF1KDJ3IIXNJIFnfGW{IEK0JIhzeyCkeTDxeYFvfGm2YYTpeoUhemWjbD30bY1mKFCFUjDhd5NigQ>? NYDlVYs4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVA1QDlpPkK0PVUxPDh7PD;hQi=>
Assay
Methods Test Index PMID
Western blot E-cadherin / N-cadherin / Snail / Vimentin ; p-Akt / Akt ; Survivin 26450645

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 409.44
Formula

C25H19N3O3

CAS No. 1127442-82-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C2C=CC1C3C2C(=O)N(C3=O)C4=CC=C(C=C4)C(=O)NC5=CC=CC6=C5N=CC=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy IWR-1-endo | IWR-1-endo supplier | purchase IWR-1-endo | IWR-1-endo cost | IWR-1-endo manufacturer | order IWR-1-endo | IWR-1-endo distributor